151 related articles for article (PubMed ID: 37711136)
1. What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome.
Fekete B; Werlenius K; Tisell M; Pivodic A; Smits A; Jakola AS; Rydenhag B
Front Surg; 2023; 10():1249366. PubMed ID: 37711136
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
3. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
5. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
6. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
9. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.
Wick W; Steinbach JP; Platten M; Hartmann C; Wenz F; von Deimling A; Shei P; Moreau-Donnet V; Stoffregen C; Combs SE
Neuro Oncol; 2013 Oct; 15(10):1405-12. PubMed ID: 23911595
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic significance of invasion in glioblastoma].
Szivós L; Virga J; Hortobágyi T; Zahuczky G; Uray I; Jenei A; Bognár L; Árkosy P; Klekner Á
Ideggyogy Sz; 2020 Sep; 73(9-10):317-325. PubMed ID: 33035418
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients.
Werlenius K; Fekete B; Blomstrand M; Carén H; Jakola AS; Rydenhag B; Smits A
PLoS One; 2020; 15(2):e0228480. PubMed ID: 32053655
[TBL] [Abstract][Full Text] [Related]
13. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
[TBL] [Abstract][Full Text] [Related]
14. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
15. Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series.
Bertolini F; Zunarelli E; Baraldi C; Valentini A; Del Giovane C; Depenni R; Falasca A; Giacobazzi P; Malagoli M; Meletti S; Fontana A; Conte P;
Tumori; 2012 Nov; 98(6):756-61. PubMed ID: 23389363
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for glioblastoma patients--a clinical population-based study.
Fekete B; Werlenius K; Örndal C; Rydenhag B
Acta Neurol Scand; 2016 Jun; 133(6):434-41. PubMed ID: 26358197
[TBL] [Abstract][Full Text] [Related]
17. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
18. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Li YM; Suki D; Hess K; Sawaya R
J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
[TBL] [Abstract][Full Text] [Related]
19. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
20. Primary glioblastoma multiforme in younger patients: a single-institution experience.
Ulutin C; Fayda M; Aksu G; Cetinayak O; Kuzhan O; Ors F; Beyzadeoglu M
Tumori; 2006; 92(5):407-11. PubMed ID: 17168433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
